Key opinion leaders in neurology Tanuja Chitnis, MD and Lauren B. Krupp, MD discuss the diagnosis and treatment of pediatric multiple sclerosis (MS) and provide insight into the impact that results from the PARADIGM trial of fingolimod in pediatric patients may have on the treatment landscape.
EP. 1: An Overview of Etiology and Prevalence of Pediatric MSMarch 30th 2021
Tanuja Chitnis, MD provides an overview of genetic, environmental, and hormonal risk factors for pediatric multiple sclerosis and discusses its prevalence based on age, sex, and geographic location.
EP. 5: Diagnostic Testing for Pediatric Multiple SclerosisApril 6th 2021
Expert neurologist Lauren B. Krupp, MD provides insight into the use of diagnostic tools for pediatric multiple sclerosis such as MRI imaging, laboratory blood tests, and lumbar punctures.
EP. 6: Emotional, Social, and Cognitive Challenges in Pediatric MSApril 13th 2021
Experts in multiple sclerosis discuss the importance of a multidisciplinary approach for pediatric patients and emphasize the role of social workers, psychologists, and support groups for patients and families.
EP. 7: Treatment Goals and Response Monitoring in Pediatric MSApril 13th 2021
Tanuja Chitnis, MD reviews the 2018 AAN guidelines on disease-modifying therapies and discusses goals of therapy when selecting first-line treatments and monitoring response in pediatric multiple sclerosis.
EP. 8: Disease-Modifying Therapy in Relapsing-Remitting MSApril 20th 2021
Leaders in neurology provide insight into first-line disease-modifying therapies for relapsing-remitting multiple sclerosis, such as interferon or glatiramer acetate, and glucocorticoids for acute events.
EP. 9: Defining Treatment Failure in Pediatric MSApril 27th 2021
Lauren B. Krupp, MD considers how treatment failure in pediatric multiple sclerosis may be defined as disease relapse, new or enlarging legions, inability to tolerate treatment, or lack of adherence.
EP. 10: Drugs and Biomarkers in Development for Pediatric MSApril 27th 2021
Expert neurologists discuss drugs in development for pediatric multiple sclerosis and consider the potential for biomarkers to monitor treatment response or new disease activity in the future.